Health care startups, take root

My name is Christina Purpura and I create marketing programs for biotech, health tech, and medtech companies. Rather than chasing clicks or views, Olive Grove would like to help you map your sector of the market, craft a plan for engagement, and gain commercial advantage.

Olive Grove serves health care startups at all stages. If your company is in the seed stage or at the Series A, I can help you break ground on your marketing approach. If you are at the Series B stage or you have phase 2 or 3 assets, I can serve as an extension of your team. For investors, I can work across your portfolio of companies or concentrate on one in particular.

How I Help You

Strategy and Partnerships

Hatch a plan for long-term growth and guide you through high-stakes institutional meetings

Research and Analysis

Comb specialized sources and outlets, conduct in-depth interviews and focus groups, attend industry presentations and gatherings, track headwinds and tailwinds for your sector

Product Marketing

Define value propositions, craft positioning, messaging and value story compendiums, devise and execute go-to-market plans, drive measurable pipeline and impact results

Narratives and Communication

Craft content strategy; send clear and persuasive messages; develop segment marketing plans

Business Development

Establish and refine playbooks, account-based marketing plans, and target lists; address sales-critical issues and design growth initiatives; conduct win-loss analyses

Events

Convene working sessions and meals with target audiences and, when appropriate, produce output with policy implications; tool you to scale the programming; develop an event strategy

Why Us

1

I spot enduring trends, not blips.

I draw on 18 years of experience working in established companies and start-ups. During my work in product marketing at a software-as-a-service company, I coauthored an influential journal article on the FDA’s growing use of real-world evidence (RWE) in regulatory decisions. Since the article’s publication, the FDA has further embraced the use of RWE. Recently I have been involved in work at the intersection of life sciences and national security, as well as programming on partnering/licensing pros and cons.

2

I guarantee human originality.

Although I use AI to improve workflow, I never use it to produce content for clients. My writing is my own—and you will notice the difference.

3

I have been there.

Having worked in venture-backed startups, a mid-sized biopharma company, and in services companies, I understand the constraints life sciences innovators face. If your company cannot yet talk about an asset or can only do so subject to guidelines, we work within those constraints.

Examples

Strategy and Partnerships

At Aetion, I mapped the real-world evidence ecosystem and built a standard-setting plan. The work uncovered new growth opportunities and positioned Aetion as a leader in the generation and use of RWE for regulatory decision-making. In 2025, Datavant acquired Aetion in a deal valued at almost $400 million.

Product Marketing

I led initiatives to expand Aetion’s product offerings related to COVID-19 and oncology. Thanks to those offerings, manufacturers can now evaluate the safety and effectiveness of medical products for infectious diseases and oncology. See, for example, our support to Janssen.

Events

At my prior firm, Arnold & Porter, I helped design an in-person series for biotechnology companies. The series covered two questions: “Should you license the asset?” and “What do you do when the deal goes wrong?” The boardroom-style discussions helped us connect companies on the buy and sell side while advancing Arnold & Porter’s brand and accelerating growth.

Olive Grove would like to help you.

Email Us
Olive Grove
Email Us © 2026 Olive Grove Strategy. All Rights Reserved.